INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)

Respiratory Papillomatosis Clinical Trial

Official title: An Open-label Multi-center Study of INO-3107 With Electroporation (EP) in Subjects With HPV-6- and/or HPV-11-associated Recurrent Respiratory Papillomatosis (RRP)

Status Completed

Clinical Trial Summary

This is a Phase 1/2 open-label, multicenter trial to evaluate the safety, tolerability, immunogenicity, and efficacy of INO-3107 in subjects with HPV-6 and/or HPV-11-associated recurrent respiratory papillomatosis (RRP). The trial population will include participants who have been diagnosed with either Juvenile-Onset RRP (J-O RRP) as defined by age at first diagnosis <12 years or with Adult- Onset RRP (A-O RRP) as defined by age at first diagnosis ≥12 years. A safety run-in will be performed with up to six participants with a one week waiting period between each enrolled participant.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Papilloma
• Papillomavirus Infections
• Respiratory Papillomatosis
• Respiratory Tract Infections

• NCT number: NCT04398433
• Study type: Interventional
• Source: Inovio Pharmaceuticals
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: June 15, 2020
• Completion date: December 15, 2022